MENU
+Compare
AUPH
Stock ticker: NASDAQ
AS OF
May 8 closing price
Price
$8.11
Change
-$0.00 (-0.00%)
Capitalization
1.11B

AUPH Aurinia Pharmaceuticals Forecast, Technical & Fundamental Analysis

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs... Show more

Industry: #Biotechnology
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for AUPH with price predictions
May 07, 2025

AUPH's RSI Indicator ascending out of oversold territory

The RSI Oscillator for AUPH moved out of oversold territory on April 09, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In of the 33 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 22, 2025. You may want to consider a long position or call options on AUPH as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AUPH just turned positive on April 22, 2025. Looking at past instances where AUPH's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

AUPH moved above its 50-day moving average on April 29, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for AUPH crossed bullishly above the 50-day moving average on May 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

AUPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where AUPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AUPH entered a downward trend on April 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.939) is normal, around the industry mean (14.238). P/E Ratio (203.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (5.048) is also within normal values, averaging (252.967).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

AUPH is expected to report earnings to rise 950.00% to 10 cents per share on May 12

Aurinia Pharmaceuticals AUPH Stock Earnings Reports
Q1'25
Est.
$0.10
Q4'24
Missed
by $0.02
Q3'24
Beat
by $0.08
Q2'24
Est.
$0.01
Q1'24
Beat
by $0.07
The last earnings report on February 27 showed earnings per share of 0 cents, missing the estimate of 2 cents. With 915.09K shares outstanding, the current market capitalization sits at 1.11B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
14315 118 Avenue
Phone
+1 250 708-4272
Employees
300
Web
https://www.auriniapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BSMAX15.44N/A
N/A
iShares Russell Small/Mid-Cap Idx Inv A
MMEYX42.44N/A
N/A
Victory Integrity Discovery Y
FINVX14.26N/A
N/A
Fidelity Series International Value
SLARX29.74N/A
N/A
DWS Latin America Equity Inst
RIVGX18.37-0.04
-0.22%
American Funds International Vntg R-6

AUPH and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
N/A
JSPR - AUPH
44%
Loosely correlated
+2.55%
VCYT - AUPH
39%
Loosely correlated
+1.20%
CMRX - AUPH
38%
Loosely correlated
N/A
SCPH - AUPH
37%
Loosely correlated
+4.15%
GOSS - AUPH
37%
Loosely correlated
+2.28%
More